Heatwurx (PCSA)
(Delayed Data from NSDQ)
$1.36 USD
-0.01 (-0.73%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.36 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
PCSA 1.36 -0.01(-0.73%)
Will PCSA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PCSA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PCSA
Heatwurx Inc. (PCSA) Upgraded to Buy: Here's What You Should Know
PCSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PCSA
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
Processa Pharmaceuticals reports GAAP EPS of -$1.01
Processa Pharmaceuticals Provides Product Pipeline and Financial Update
Processa Pharmaceuticals reports Q2 EPS ($1.01) vs. ($1.94) last year
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri